thalidomide has been researched along with Cholecystoduodenal Fistula in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fistulas are common in patients with Crohn's disease and, when associated with inflammatory disease and established for several weeks, tend to be chronic." | 2.41 | Management of fistulas in patients with Crohn's disease: antibiotic to antibody. ( Paré, P, 2001) |
| "Postoperative pathology confirmed Crohn's disease." | 1.48 | [The 465th case: intestinal obstruction, gastrointestinal hemorrhage and duodenal fistula]. ( Guo, F; Li, JN; Li, XQ; Ma, ZQ; Qian, JM; Wang, YN; Xue, HD; Yang, AM; Zhou, WX, 2018) |
| "Fistulizing Crohn's disease is associated with significant morbidity." | 1.35 | Editorial: Imaging and the treatment of Crohn's perianal fistulas: to see is to believe. ( Schwartz, DA, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, YN | 1 |
| Li, XQ | 1 |
| Guo, F | 1 |
| Yang, AM | 1 |
| Qian, JM | 1 |
| Li, JN | 1 |
| Xue, HD | 1 |
| Zhou, WX | 1 |
| Ma, ZQ | 1 |
| Ng, SC | 1 |
| Plamondon, S | 1 |
| Gupta, A | 1 |
| Burling, D | 1 |
| Swatton, A | 1 |
| Vaizey, CJ | 1 |
| Kamm, MA | 1 |
| Schwartz, DA | 1 |
| Rutgeerts, P | 1 |
| Van Assche, G | 1 |
| Vermeire, S | 1 |
| Paré, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Longitudinal Study on the Effect of Tight Control Management on Perianal Crohn's Disease[NCT03861689] | 40 participants (Anticipated) | Interventional | 2019-07-01 | Enrolling by invitation | |||
| Stopping Biological Therapy in Perianal Crohn's Disease Patients With Radiologically Healed Fistulas: a Prospective Cohort Study[NCT04129723] | 0 participants (Actual) | Interventional | 2022-01-01 | Withdrawn (stopped due to No suitable case identified) | |||
| Impact of Anti-TNF Antibodies on the T-lymphocyte and Macrophage Cooperation in the Crohn Disease[NCT00561548] | 20 participants (Anticipated) | Interventional | 2007-05-31 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thalidomide and Cholecystoduodenal Fistula
| Article | Year |
|---|---|
Optimizing anti-TNF treatment in inflammatory bowel disease.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Certolizumab Pegol; Crohn Dis | 2004 |
Management of fistulas in patients with Crohn's disease: antibiotic to antibody.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Azathioprine; Colonic Diseases; Crohn Disease; Cyclos | 2001 |
3 other studies available for thalidomide and Cholecystoduodenal Fistula
| Article | Year |
|---|---|
[The 465th case: intestinal obstruction, gastrointestinal hemorrhage and duodenal fistula].
Topics: Anastomosis, Surgical; Colon; Crohn Disease; Cutaneous Fistula; Digestive System Surgical Procedures | 2018 |
Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2009 |
Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2009 |
Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2009 |
Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2009 |
Editorial: Imaging and the treatment of Crohn's perianal fistulas: to see is to believe.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2009 |